Summary
The effects and plasma concentrations of different doses of propranolol and metoprolol were studied in 34 hyperthyroid patients. The initial daily doses were propranolol 160 mg or metoprolol 200 mg. If the resting heart rate remained above 75 beats per min after treatment for 4–7 days, the dose was increased and the patient re-examined after a further 4–7 days. Propranolol (n=17) caused a reduced heart rate, a decrease in serum 3,3′,5-triiodothyronine (T3) and an increase in serum 3,3′,5′-triiodothyronine (reverse T3, rT3). In 10 patients, there was no change in T3 or rT3 until the daily dose of propranolol had been increased to 240 or 320 mg. The plasma level of propranolol was significantly correlated with the decrease in T3 and the increase in rT3. Metoprolol (n=17) caused a reduction in heart rate similar to that following propranolol. However, serum T3 was only slightly reduced even after an increase in dose to 300 or 400 mg, and serum rT3 was not altered. Metoprolol concentrations were not significantly correlated with the fall in T3. It appears that the influence ofβ-blockers on T4 conversion is of little importance for the clinical improvement in hyperthyroid patients, and rather it is a consequence ofβ 1-adrenergic blockade interfering with the effect of T3. In addition, the findings support the assumption that therapeutic failure withβ-blockers in hyperthyroidism may be due to suboptimal treatment, and that individualized dosage is necessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burman KD, Dimond FD, Wright PD, Earll JM, Bruton J, Wartofsky L (1977) A radioimmunoassay for 3,3′,5′-L-triiodothyronine (Reverse T3): Assessment of thyroid gland content and serum measurements in conditions of normal and altered thyroidal economy and following administration of thyrotrophin releasing hormone (TRH) and thyrotrophin (TSH). J Clin Endocrinol Metab 44: 660–672
Crooks J, Murray IPC, Wayne EJ (1959) Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med 28: 211–234
Ervik M (1975) Quantitative determination of metoprolol in plasma and urine by gas chromatography. Acta Pharmacol Toxicol 36: 136–144
Etzkorn J, Hopkins P, Gray J, Segal J, Ingbar SH (1979) Beta-adrenergic potentiation of the increased in vitro accumulation of cycloeucine by rat thymocytes induced by triiodothyronine. J Clin Invest 63: 1172–1180
Feely J, Stevenson IH (1978) The effect of age and hyperthyroidism on plasma propranolol steady state concentration. Br J Clin Pharmacol 6: 446 P
Feely J, Isles TE, Ratcliffe WA, Crooks J (1979) Propranolol, triiodothyronine, reverse triiodothyronine and thyroid disease. Clin Endocrinol 10: 531–538
Grossman W, Robin NI, Johnson LW, Brooks H, Selenkow HA, Dexter L (1971) Effects of beta-blockade on the peripheral manifestations of thyrotoxicosis. Ann Intern Med 74: 875–879
Harrower ADB, Fyffe JA, Horn DB, Strong JA (1977) Thyroxine and triiodothyronine levels in hyperthyroid patients during treatment with propranolol. Clin Endocrinol 7: 41–44
Hellman R, Kelly KL, Mason WD (1977) Propranolol for thyroid storm. Correspondence. N Engl J Med 297: 671–672
Heyma P, Larkins RG, Higginbotham L, Wah NgK (1980) D-Propranolol and DL-propranolol both decrease conversion of L-thyroxine to L-triiodothyronine. Br Med J 281: 24–25
Kallner G, Ljunggren J-G, Tryselius M (1978) The effect of propranolol on serum levels of T4, T3 and reverse-T3 in hyperthyroidism. Acta Med Scand 204: 35–37
Lotti G, Delitala G, Devilla L, Alagna S, Masala A (1977) Reduction of plasma triiodothyronine (T3) induced by propranolol. Clin Endocrinol 6: 405–410
Lumholtz IB, Siersbaek-Nielsen K, Faber J, Kirkegaard C, Friis T (1978) Effect of propranolol on extrathyroidal metabolism of thyroxine and 3,3′,5-triiodothyronine evaluated by noncompartmental kinetics. J Clin Endocrinol Metab 47: 587–589
McDevitt DG, Nelson JK (1978) Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol 6: 233–237
Mitsuma T, Colucci J, Shenkman L, Hollander CS (1972) Rapid simultaneous radioimmunoassay for triiodothyronine and thyroxine in unextracted serum. Biochem Biophys Res Commun 46: 2107–2113
Murchison LE, Bewsher PD, Chesters MI, Ferrier WR (1976) Comparison of propranolol and practolol in the management of hyperthyroidism. Br J Clin Pharmacol 3: 273–277
Murchison LE, How J, Bewsher PD (1979) Comparison of propranolol and metoprolol in the management of hyperthyroidism. Br J Clin Pharmacol 8: 581–587
Nilsson OR, Karlberg BE, Kågedal B, Tegler L, Almqvist S (1979) Non-selective and selectiveβ 1-adrenoceptor blocking agents in the treatment of hyperthyroidism. Acta Med Scand 206: 21–25
Pritchard JF, Schneck DW, Hayes Jr. AH (1979) Determination of propranolol and six metabolites in human urine by high-pressure liquid chromatography. J Chromatogr 162: 47–58
Ramsay I (1975) Adrenergicβ-receptor blockade in hyperthyroidism. Br J Pharmacol 2: 385–386
Rubenfeld S, Silverman VE, Welch KMA, Malette LE, Kohler PO (1979) Variable plasma propranolol levels in thyrotoxicosis. N Engl J Med 300: 353–354
Shand DG (1975) Drug theraphy: propranolol (review). N Engl J Med 293: 280–285
Shanks RG, Lowe DC, Hadden DR, McDevitt DG, Montgomery DAD (1969) Controlled trial of propranolol in thyrotoxicosis. Lancet 1: 993–994
Theilade P, Hansen JM, Skovsted L, Faber J, Kirkegaard C, Friis T, Siersbaek-Nielsen K (1977) Propranolol influences serum T3 and reverse T3 in hyperthyroidism. Lancet 2: 363
Verhoeven RP, Visser TJ, Docter R, Henneman G, Schalekamp MADH (1977) Plasma thyroxine, 3,3′,5-triiodothyronine and 3,3′,5′-triiodothyronine duringβ-adrenergic blockade in hyperthyroidism. J Clin Endocrinol Metab 44: 1002–1005
Wiersinga WM, Touber JL (1977) The influence ofβ-adrenoceptor blocking agents on plasma thyroxine and triiodothyronine. J Clin Endocrinol Metab 45: 293–298
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nilsson, O.R., Melander, A. & Tegler, L. Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients. Eur J Clin Pharmacol 18, 315–320 (1980). https://doi.org/10.1007/BF00561388
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561388